Optimize Cell Culture Conditions and Maximize Production Webinar - Thursday, Oct 29th. Register Now >
Dean joined GTCR in 2001 and is currently a Managing Director of the firm. Prior to joining GTCR, Dean was CEO and co-founder of Delray Farms, LLC, a specialty food retailer. Prior to Delray Farms, Dean was with McKinsey & Company. Dean holds an MBA with distinction from the Harvard Business School and a BS with high distinction in finance and economics from the University of Illinois, Chicago.
Dean is head of the Healthcare group at GTCR and has been instrumental in building the firm’s expertise in life sciences and medical devices. In addition to serving as a Director of Cole-Parmer, he is currently a Director of Albany Molecular, Cebatech, Cedar Gate Technologies, Corza Health, Maravai LifeSciences, Riverchase Dermatology, Regatta Medical, Rx30, Sotera, TerSera and XIFIN. Dean was previously a Director of past GTCR investments, including Actient Pharmaceuticals, ATI Physical Therapy, Convergex, Cord Blood Registry, Crealta Pharmaceuticals, Curo Health Services, Dash, Devicor Medical Products, GreatCall, Ovation Pharmaceuticals, Managed Healthcare Associates and Polypore.
Dean’s interest in the community is evident by his strong support of WBEZ Chicago Public Media, a non-commercial, public radio station financed primarily by listener contributions, where he serves as a board member and chair of the finance committee.
Sean joined GTCR in 2001 and is currently a Managing Director of the firm. He was previously a Consultant with The Boston Consulting Group. Sean holds an MBA from the Wharton School at the University of Pennsylvania as well as AB and BE degrees in engineering sciences from Dartmouth College.
In addition to serving as Director of Cole-Parmer, Sean currently is a Director of Albany Molecular Research, Ceba-Tech, Cedar Gate Technologies, Corza Health, Maravai LifeSciences, Regatta, Riverchase Dermatology, Sotera and Transaction Data Systems. He was instrumental in GTCR’s past investments in Cord Blood Registry, Devicor Medical Products, Graceway Pharmaceuticals and Ovation Pharmaceuticals.
Ben joined GTCR in 2008 and is currently a Managing Director of the firm. Prior to joining GTCR, he worked as a Venture Capitalist at Alta Partners, as well as an Investment Banking Associate at JMP Securities and an Analyst in the Mergers & Acquisitions group at J.P. Morgan (formerly Hambrecht & Quist). He holds an MBA from the Wharton School at the University of Pennsylvania and a BA in history magna cum laude from Colgate University. Ben also holds a master’s degree in biotechnology from the School of Applied Sciences & Engineering at the University of Pennsylvania.
In addition to serving as a Director of Cole-Parmer, he is currently a Director of Albany Molecular Research, Corza Health, Maravai LifeSciences, TerSera and XIFIN.
Ben was previously a Director of past GTCR investments such as Actient Pharmaceuticals and Cord Blood Registry, Crealta Pharmaceuticals, Devicor Medical Products, GeneraMedix and Sterigenics. In addition, Ben was involved in transactions with past GTCR investments ATI Physical Therapy and Graceway Pharmaceuticals.
Ben is active in the community and serves on the executive board of Spark Program, a national non-profit that provides transformative apprenticeships for at-risk middle-school students.
Greg Lucier serves as the CEO of Corza Health and founded Corza Health in partnership with GTCR to combine his 30+ years of life sciences leadership with GTCR’s unrivaled track record of creating unique, value-generating private equity opportunities.
Greg most recently served as CEO at NuVasive, a world leader in minimally invasive spine surgery technology. Prior to that, he was CEO at Life Technologies—formerly Invitrogen—which he grew into a global life sciences powerhouse that was acquired by Thermo Fisher Scientific. He spent the first part of his career with the General Electric Company in a variety of executive roles.
In addition to serving as a Director of Cole-Parmer, Lucier remains the Chairman of Nuvasive, and serves on several public and private company boards, including Catalent, a leader in advanced pharmaceutical manufacturing services, Dentsply Sirona, a global provider of professional dental products and technologies, and Epic Sciences, a venture-backed company revolutionizing the use of cellular imaging to change cancer therapy.